Edgar Jacoby

USPTO Granted Patents = 13 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 13)

Average Co-Inventor Count = 9.2

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

Basel, CH (2012 - 2015)
Beerse, BE (2021)
Vosselaar, BE (2017 - 2022)

Company Filing History:

7 out of 2,076

Janssen Pharmaceutica Nv

Janssen Sciences Ireland Unlimited Company

patents

Years Active: 2012-2022

Loading Chart...

13 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11491148 - Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases (2022-11-08),

2. 11236084 - Substituted azaindoline derivatives as NIK inhibitors (2022-02-01),

3. 11186589 - Cyanoindoline derivatives as NIK inhibitors (2021-11-30),

4. 11180487 - Substituted cyanoindoline derivatives as NIK inhibitors (2021-11-23),

5. 11136311 - Heteroaromatic derivatives as NIK inhibitors (2021-10-05),

6. 11096931 - Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases (2021-08-24),

7. 11053248 - [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors (2021-07-06),

8. 11001569 - 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors (2021-05-11),

9. 10947242 - [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors (2021-03-16),

10. 9649314 - Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones (2017-05-16),

11. 9051279 - Substituted isoquinolinones and quinazolinones (2015-06-09),

12. 8440693 - Substituted isoquinolinones and quinazolinones (2013-05-14),

13. 8163773 - Organic compounds (2012-04-24),

Title: Unveiling the Inventive Journey of Edgar Jacoby

Introduction:

Edgar Jacoby, a brilliant inventor hailing from Vosselaar, Belgium, has left an indelible mark in the field of pharmaceutical innovations. With an impressive portfolio of 13 patents, his contributions resonate in the realm of treating chronic hepatitis B virus infection, as well as addressing a myriad of diseases through innovative pharmaceutical agents.

Latest Patents:

His latest patents exemplify his dedication to advancing healthcare and therapeutic solutions. The first patent revolves around amide derivatives beneficial in treating HBV infection or HBV-induced diseases. The second patent showcases substituted azaindoline derivatives as NIK inhibitors, offering promising avenues in combating cancer, inflammatory disorders, metabolic conditions, and autoimmune diseases.

Career Highlights:

Edgar Jacoby's professional journey has been enriched by his tenure at esteemed pharmaceutical companies such as Janssen Pharmaceutica NV and Novartis AG. His expertise and inventive prowess have undoubtedly played a pivotal role in shaping groundbreaking pharmaceutical products and treatment modalities.

Collaborations:

Throughout his career, Edgar Jacoby has collaborated with esteemed colleagues such as George Hynd and Samuel Edward Mann. Together, they have synergized their expertise to drive innovation, develop cutting-edge therapies, and contribute significantly to the healthcare landscape.

Conclusion:

In conclusion, Edgar Jacoby emerges as a trailblazing inventor whose passion for scientific discovery and commitment to advancing healthcare have catalyzed transformative breakthroughs in the pharmaceutical industry. His patents stand as a testament to his ingenuity and unwavering dedication to improving global health outcomes, making him a revered figure in the realm of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.